Another Arizona Senate Committee Approves Bill To Legalize Psilocybin Service Centers, Sending It To The Floor

Another Arizona Senate committee has approved a bipartisan bill that would legalize psilocybin service centers where people could receive the psychedelic in a medically supervised setting, sending it to the floor.

On Monday, the Senate Rules Committee passed the legislation from Sen. T. J. Shope (R) in a 5-2 vote. This comes about one week after the Senate Health and Human Services Committee, which the sponsor chairs, unanimously approved the psychedelics measure.

The bill has now been placed on the consent calendar for a floor vote for a third and final reading, indicating that it’s not considered controversial—though it may still be moved off of consent in order to consider amendments. If the measure advances through the chamber, it will then move to the House for consideration.

Under the bill, the Department of Human Services (DHS) would be authorized to license psilocybin-assisted therapy centers in the state, where trained facilitators could administer the psychedelic.

The legislation would significantly expand on Arizona’s existing research-focused psychedelics law that provides $5 million in annual funding to support studies into psilocybin therapy.

Shope’s proposal would establish an Arizona Psilocybin Advisory Board, comprised of members appointed by the governor and legislative leaders. Representatives of the attorney general’s office and DHS, as well as military veterans, first responders, scientists with experience with psilocybin and physicians would be among the members.

The board would be responsible for establishing training criteria for psilocybin service center staff, making recommendations on the implementation of the law, and studying the science and policy developments related to psychedelics.

By July 31, 2025 and each year after that, members would need to submit an annual report on the status of “medical, psychological and scientific” studies into the safety and efficacy of psilocybin, as well as a “long-term strategic plan” on ensuring that psychedelic-assisted therapy remains “safe, accessible and affordable” to people 21 and older.

Medical directors of psychedelic-assisted therapy centers would need to complete at least 132 hours of training under an approved program, which would need to involve lessons on the historical and traditional use of psychedelics, safety and ethics, facilitation skills and preparation, administration and integration.

The bill, which is cosponsored by Senate President Warren Petersen (R), states that DHS would need to start accepting applications for psychedelics centers by January 1, 2026. The department would need to promulgate rules for the program, but it would be barred from requiring specific eligible conditions for participation in psilocybin services.

Regulators could also license psilocybin centers that are carrying out clinical trials into the psychedelic that could lead to a Food and Drug Administration-approved drug.

Joe DeMenna, who represents the group Citizens for Psilocybin, told Marijuana Moment that he’s familiar with talks of moving the bill from the consent calendar in order to adopt an amendment dealing with psilocybin sourcing and examining the possibility of allowing the psychedelic to be administered off-site for people in hospice and end of life care who could not access the service centers.

“The latter is a long shot but needs to be considered,” he said. “If my understanding is correct, it will take at least a week to work out those details and then push it to third read so it can quickly get over to the House.”

Meanwhile, last month an Arizona House committee approved a separate bill to protect the $5 million in funding that’s already been designated for psilocybin research from being redistributed amid a state budget deficit.

The fund was enacted last year under an appropriations package signed by the governor that mandated research into the medical potential of psilocybin mushrooms for a variety of conditions.

A Psilocybin Research Advisory Council that was established under DHS met for the first time last November prior an open application period for potential grant recipients.

The grant money must be distributed to applicants with proposals focused on clinical trials that are meant to identify therapeutic applications that could receive FDA approval for treatment of 13 listed conditions.

Arizona one of several states where lawmakers have worked to promote research into psychedelics amid growing public interest in expanding therapeutic access and ending criminalization.

—Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.—

Last week, for example, an Alaska Senate committee advanced a bill that would create a task force to study how to license and regulate psychedelic-assisted therapy in anticipation of eventual federal legalization of substances like MDMA and psilocybin.

Lawmakers in Hawaii are also continuing to advance a bill that would provide some legal protections to patients engaging in psilocybin-assisted therapy with a medical professional’s approval.

The New Mexico Senate unanimously approved a bipartisan resolution last week requesting that state officials research the therapeutic potential of psilocybin and explore the creation of a regulatory framework to provide access to the psychedelic.

Last week, an Indiana House committee approved a Republican-led bill that would fund clinical research trials into psilocybin that has already cleared the full Senate.

Bipartisan California lawmakers also recently introduced a bill to legalize psychedelic service centers where adults 21 and older could access psilocybin, MDMA, mescaline and DMT in a supervised environment with trained facilitators.

A Nevada joint legislative committee held a hearing with expert and public testimony on the therapeutic potential of substances like psilocybin last month. Law enforcement representatives also shared their concerns around legalization—but there was notable acknowledgement that some reforms should be enacted, including possible rescheduling.

The governor of Massachusetts recently promoted the testimony of activists who spoke in favor of her veterans-focused bill that would, in part, create a psychedelics work group to study the therapeutic potential of substances such as psilocybin.

A New York lawmaker recently introduced a bill that would create a pilot program to provide psilocybin therapy to 10,000 people, focusing on military veterans and first responders, while the legislature also considers broader psychedelics reform.

A Missouri House committee considered a proposal last month that would legalize the medical use of psilocybin in the state and mandate clinical trials exploring the therapeutic potential of the psychedelic.

Back in Arizona, meanwhile, a House committee approved a bill last week to authorize interstate marijuana commerce, pending a change in federal policy.

Where Presidential Candidate Donald Trump Stands On Marijuana

Photo courtesy of Dick Culbert.